The DOI matches its Crossref record; 183 of the 183 references it cites were found in a registry or an index.
Molecular mechanisms of L-DOPA-induced dyskinesia
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Van Den Eeden, S. K. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,747
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,454
Surmeier, D. J., Ding, J., Day, M., Wang, Z., & Shen, W. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.008 · Cited by 1,203
Circuits and Circuit Disorders of the Basal Ganglia
DeLong, M. R., & Wichmann, T. (2007) · Archives of Neurology · doi:10.1001/archneur.64.1.20 · Cited by 1,074
The epidemiology of Parkinson's disease
Ben-Shlomo, Y., Darweesh, S., Llibre-Guerra, J., Marras, C., San Luciano, M., & Tanner, C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01419-8 · Cited by 967
Kühn, A. A., Kupsch, A., Schneider, G., & Brown, P. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04717.x · Cited by 892
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
Pathophysiology of the basal ganglia in Parkinson's disease
Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., & Olanow, C. W. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00028-8 · Cited by 844
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
Day, M., Wang, Z., Ding, J., An, X., Ingham, C. A., Shering, A. F., Wokosin, D., Ilijic, E., Sun, Z., Sampson, A. R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1632 · Cited by 745 · cited 1×
“Administration of the monoamine depletor reserpine or of 6-OHDA leads to spine loss and to alterations in corticostriatal connectivity that are limited to the medium spiny neurons of the indirect output pathwa”
BackgroundLundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., & Cenci, M. A. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01843.x · Cited by 664
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Bjorklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 636
Ballard, P. A., Tetrud, J. W., & Langston, J. W. (1985) · Neurology · doi:10.1212/wnl.35.7.949 · Cited by 629
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Olanow, C. W., Obeso, J. A., & Stocchi, F. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70521-x · Cited by 547
(2023) · Elsevier eBooks · doi:10.1016/c2021-0-02248-3 · Cited by 542
Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
Metman, L. V., Del Dotto, P., van den Munckhof, P., Fang, J., Mouradian, M. M., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5.1323 · Cited by 514
Levodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478
Fabbrini, G., Brotchie, J. M., Grandas, F., Nomoto, M., & Goetz, C. G. (2007) · Movement Disorders · doi:10.1002/mds.21475 · Cited by 464
Animal models of neurological deficits: how relevant is the rat?
Cenci, M. A., Whishaw, I. Q., & Schallert, T. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn877 · Cited by 456
Young onset Parkinson's disease
Quinn, N., Critchley, P., & Marsden, C. D. (1987) · Movement Disorders · doi:10.1002/mds.870020201 · Cited by 443
Li, W., Cui, Y., Kushner, S. A., Brown, R. A. M., Jentsch, J. D., Frankland, P. W., Cannon, T. D., & Silva, A. J. (2005) · Current Biology · doi:10.1016/j.cub.2005.09.043 · Cited by 402
Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia
Aubert, I., Guigoni, C., Håkansson, K., Li, Q., Dovero, S., Barthe, N., Bioulac, B. H., Gross, C. E., Fisone, G., Bloch, B., et al. (2005) · Annals of Neurology · doi:10.1002/ana.20296 · Cited by 387
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
Bézard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C., & Sokoloff, P. (2003) · Nature Medicine · doi:10.1038/nm875 · Cited by 383
Levodopa in the treatment of Parkinson's disease: Current controversies
Olanow, C. W., Agid, Y., Mizuno, Y., Albanese, A., Bonucelli, U., Damier, P., De Yebenes, J., Gershanik, O., Guttman, M., Grandas, F., et al. (2004) · Movement Disorders · doi:10.1002/mds.20243 · Cited by 370
Self-citationA comparison of clinical and pathological features of young‐ and old‐onset Parkinson's disease
Gibb, W. R. G., & Lees, A. J. (1988) · Neurology · doi:10.1212/wnl.38.9.1402 · Cited by 369
Principles and Practice of Movement Disorders
(2007) · Elsevier eBooks · doi:10.1016/b978-0-443-07941-2.x5001-3 · Cited by 366
Gr�nblatt, E., Mandel, S., Jacob-Hirsch, J., Zeligson, S., Amariglo, N., Rechavi, G., Li, J., Ravid, R., Roggendorf, W., Riederer, P., et al. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0212-1 · Cited by 356
Andersson, M., Hilbertson, A., & Cenci, M. A. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0259 · Cited by 350
Competition between Feedback Loops Underlies Normal and Pathological Dynamics in the Basal Ganglia
Leblois, A., Boraud, T., Meissner, W., Bergman, H., & Hansel, D. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5050-05.2006 · Cited by 349
Induction of dopamine D 3 receptor expression as a mechanism of behavioral sensitization to levodopa
Bordet, R., Ridray, S., Carboni, S., Diaz, J., Sokoloff, P., & Schwartz, J.-C. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.7.3363 · Cited by 345
The Yin and Yang of dopamine release: a new perspective
GOTO, Y., OTANI, S., & GRACE, A. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.007 · Cited by 342
Pavón, N., Martín, A. B., Mendialdua, A., & Moratalla, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.05.044 · Cited by 341
Levodopa‐induced dyskinesias improved by a glutamate antagonist in parkinsonia monkeys
Papa, S. M., & Chase, T. N. (1996) · Annals of Neurology · doi:10.1002/ana.410390505 · Cited by 292
Ingham, C. A., Hood, S. H., Taggart, P., & Arbuthnott, G. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-12-04732.1998 · Cited by 291
Evidence of a breakdown of corticostriatal connections in Parkinson’s disease
Stephens, B., Mueller, A. J., Shering, A. F., Hood, S. H., Taggart, P., Arbuthnott, G. W., Bell, J. E., Kilford, L., Kingsbury, A. E., Daniel, S. E., et al. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.01.007 · Cited by 284
Westin, J. E., Vercammen, L., Strome, E. M., Konradi, C., & Cenci, M. A. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.11.032 · Cited by 277
Single-axon tracing study of neurons of the external segment of the globus pallidus in primate
Sato, F., Lavall�e, P., L�vesque, M., & Parent, A. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000131)417:1<17::aid-cne2>3.0.co;2-i · Cited by 277
Neural mechanisms in disorders of movement
Crossman, A. R. (1989) · Comparative Biochemistry and Physiology Part A: Physiology · doi:10.1016/0300-9629(89)90201-6 · Cited by 275
Grace, A. A. (1995) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(94)01066-t · Cited by 274
A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia
Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Di Luca, M., & Calabresi, P. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.5326-05.2006 · Cited by 269
Dunah, A. W., Wang, Y., Yasuda, R. P., Kameyama, K., Huganir, R. L., Wolfe, B. B., & Standaert, D. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23206-5 · Cited by 263
Hauser, R. A., Rascol, O., Korczyn, A. D., Jon Stoessl, A., Watts, R. L., Poewe, W., De Deyn, P. P., & Lang, A. E. (2007) · Movement Disorders · doi:10.1002/mds.21743 · Cited by 252
Gunne, L.-M., Häggström, J.-E., & Sjöquist, B. (1984) · Nature · doi:10.1038/309347a0 · Cited by 251
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism
Chase, T. N., & Oh, J. D. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00018-5 · Cited by 251
Atrophy of medium spiny I striatal dendrites in advanced Parkinson's disease
McNeill, T. H., Brown, S. A., Rafols, J. A., & Shoulson, I. (1988) · Brain Research · doi:10.1016/0006-8993(88)90124-2 · Cited by 246
Crossman, A. R. (1990) · Movement Disorders · doi:10.1002/mds.870050203 · Cited by 245
Be´dard, P. J., Paolo, T. D., Falardeau, P., & Boucher, R. (1986) · Brain Research · doi:10.1016/0006-8993(86)90783-3 · Cited by 244
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease
Vitek, J. L., Bakay, R. A. E., Freeman, A., Evatt, M., Green, J., McDonald, W., Haber, M., Barnhart, H., Wahlay, N., Triche, S., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10517 · Cited by 243
A Critical Role of the Nitric Oxide/cGMP Pathway in Corticostriatal Long-Term Depression
Calabresi, P., Gubellini, P., Centonze, D., Sancesario, G., Morello, M., Giorgi, M., Pisani, A., & Bernardi, G. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02489.1999 · Cited by 232
Stocchi, F., Vacca, L., Ruggieri, S., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229
Calon, F., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Di Paolo, T. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.07.003 · Cited by 220
Dekundy, A., Lundblad, M., Danysz, W., & Cenci, M. A. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.01.013 · Cited by 219
Pearce, R. K. B., Jackson, M., Smith, L., Jenner, P., & Marsden, C. D. (1995) · Movement Disorders · doi:10.1002/mds.870100606 · Cited by 218
Self-citationMedical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease
Jankovic, J., & Stacy, M. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00005 · Cited by 213
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
Calon, F. (2004) · Brain · doi:10.1093/brain/awh128 · Cited by 212
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., et al. (2006) · Movement Disorders · doi:10.1002/mds.20724 · Cited by 210
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys
Konitsiotis, S., Blanchet, P. J., Verhagen, L., Lamers, E., & Chase, T. N. (2000) · Neurology · doi:10.1212/wnl.54.8.1589 · Cited by 201
Nondopaminergic mechanisms in levodopa‐induced dyskinesia
Brotchie, J. M. (2005) · Movement Disorders · doi:10.1002/mds.20612 · Cited by 192
Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., & Standaert, D. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.008 · Cited by 192
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs
Cedarbaum, J. M. (1987) · Clinical Pharmacokinetics · doi:10.2165/00003088-198713030-00002 · Cited by 187
Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys
Blanchet, P. J., Konitsiotis, S., & Chase, T. N. (1998) · Movement Disorders · doi:10.1002/mds.870130507 · Cited by 185
Piccini, P., Weeks, R. A., & Brooks, D. J. (1997) · Annals of Neurology · doi:10.1002/ana.410420508 · Cited by 177
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
Schapira, A. H. V., & Obeso, J. (2006) · Annals of Neurology · doi:10.1002/ana.20789 · Cited by 177
Functional neuroanatomy of the basal ganglia in Parkinson's disease.
Wichmann, T., & DeLong, M. R. (2003) · PubMed · Cited by 169
Obeso, J. A., Rodriguez-Oroz, M., Marin, C., Alonso, F., Zamarbide, I., Lanciego, J. L., & Rodriguez-Diaz, M. (2004) · Neurology · doi:10.1212/wnl.62.1_suppl_1.s17 · Cited by 169
Di Monte, D. A., McCormack, A., Petzinger, G., Janson, A. M., Quik, M., & Langston, W. J. (2000) · Movement Disorders · doi:10.1002/1531-8257(200005)15:3<459::aid-mds1006>3.0.co;2-3 · Cited by 165
Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications.
Chase, T. N., & Oh, J. D. (2000) · PubMed · Cited by 164
Fox, S. H., Henry, B., Hill, M., Crossman, A., & Brotchie, J. (2002) · Movement Disorders · doi:10.1002/mds.10289 · Cited by 164
Development of dyskinesias in a 5‐year trial of ropinirole and L ‐dopa
Rascol, O., Brooks, D. J., Korczyn, A. D., Deyn, P. P. D., Clarke, C. E., Lang, A. E., & Abdalla, M. (2006) · Movement Disorders · doi:10.1002/mds.20988 · Cited by 161
Late emergence of synchronized oscillatory activity in the pallidum during progressive parkinsonism
Leblois, A., Meissner, W., Bioulac, B., Gross, C. E., Hansel, D., & Boraud, T. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05777.x · Cited by 160
Transcriptome analysis in a rat model of l-DOPA-induced dyskinesia
Konradi, C., Westin, J. E., Carta, M., Eaton, M. E., Kuter, K., Dekundy, A., Lundblad, M., & Cenci, M. A. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.005 · Cited by 159
How common are complications of Parkinson's disease?
Schrag, A. E., Ben‐Shlomo, Y., & Quinn, N. P. (2002) · Journal of Neurology · doi:10.1007/s004150200032 · Cited by 159
Savola, J., Hill, M. P., Engström, M., Merivuori, H., Wurster, S., McGuire, S. G., Fox, S. H., Crossman, A. R., & Brotchie, J. M. (2003) · Movement Disorders · doi:10.1002/mds.10464 · Cited by 159
MANDEL, S., GRUNBLATT, E., RIEDERER, P., AMARIGLIO, N., HIRSCH, J. J., RECHAVI, G., & YOUDIM, M. B. H. (2005) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2005.tb00044.x · Cited by 158
Vila, M., Levy, R., Herrero, M.-T., Ruberg, M., Faucheux, B., Obeso, J. A., Agid, Y., & Hirsch, E. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00765.1997 · Cited by 158
Corvol, J.-C., Muriel, M.-P., Valjent, E., Féger, J., Hanoun, N., Girault, J.-A., Hirsch, E. C., & Hervé, D. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0676-04.2004 · Cited by 158
Blanchet, P. J., Konitsiotis, S., Whittemore, E. R., Zhou, Z. L., Woodward, R. M., & Chase, T. N. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35003-7 · Cited by 158
Dotto, P. D., Pavese, N., Gambaccini, G., Bernardini, S., Metman, L. V., Chase, T. N., & Bonuccelli, U. (2001) · Movement Disorders · doi:10.1002/mds.1112 · Cited by 153
Oh, J. D., Russell, D., Vaughan, C. L., & Chase, T. N. (1998) · Brain Research · doi:10.1016/s0006-8993(98)01049-x · Cited by 153
Drug Insight: continuous dopaminergic stimulation in the treatment of Parkinson's disease
Olanow, C., Obeso, J., & Stocchi, F. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0222 · Cited by 150
Morelli, M., Paolo, T. D., Wardas, J., Calon, F., Xiao, D., & Schwarzschild, M. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.07.001 · Cited by 146
Ingham, C. A., Hood, S. H., van Maldegem, B., Weenink, A., & Arbuthnott, G. W. (1993) · Experimental Brain Research · doi:10.1007/bf00227776 · Cited by 144
Blanchet, P. J., Calon, F., Martel, J.-C., Bédard, P. J., Paolo, T. D., Walters, R. R., & Piercey, M. F. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24503-7 · Cited by 142
Tahar, A. H., Grégoire, L., Dare, A., Bélanger, N., Meltzer, L. T., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.007 · Cited by 141
Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors
Guigoni, C., Aubert, I., Li, Q., Gurevich, V. V., Benovic, J., Ferry, S., Mach, U., Stark, H., Leriche, L., Håkansson, K., et al. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.11.005 · Cited by 141
Henry, B. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00064-5 · Cited by 141
The neuropathological effects of antipsychotic drugs
Harrison, P. J. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00065-1 · Cited by 139
Herrero, M. T., Augood, S. J., Hirsch, É. C., Javoy-Agid, F., Luquín, M. R., Agid, Y., Obeso, J. A., & Emson, P. C. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00120-8 · Cited by 139
Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates
Guigoni, C., Doudnikoff, É., Li, Q., Bloch, B., & Bézard, E. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.02.001 · Cited by 136
Bordet, R., Ridray, S., Schwartz, J.-C., & Sokoloff, P. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00089.x · Cited by 135
Bibbiani, F., Oh, J. D., Kielaitė, A., Collins, M. A., Smith, C., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.017 · Cited by 133
Parkin, S., Gregory, R., Scott, R., Bain, P., Silburn, P., Hall, B., Boyle, R., Joint, C., & Aziz, T. (2002) · Movement Disorders · doi:10.1002/mds.10186 · Cited by 133
Westin, J. E., Andersson, M., Lundblad, M., & Cenci, M. A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01743.x · Cited by 129
Antiparkinsonian Actions of Ifenprodil in the MPTP-Lesioned Marmoset Model of Parkinson's Disease
Nash, J. E., Fox, S. H., Henry, B., Hill, M. P., Peggs, D., McGuire, S., Maneuf, Y. P., Hille, C. J., Brotchie, J. M., & Crossman, A. R. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7444 · Cited by 127
Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?
Calabresi, P. A., Giacomini, P., Centonze, D., & Bernardi, G. (2000) · PubMed · Cited by 123
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates
Bibbiani, F., Costantini, L. C., Patel, R., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.11.013 · Cited by 123
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
Picconi, B., Paillé, V., Ghiglieri, V., Bagetta, V., Barone, I., Lindgren, H. S., Bernardi, G., Cenci, M. A., & Calabresi, P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.10.001 · Cited by 122
Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease
Metman, V. L., Dotto, D. P., Natté, R., van den Munckhof, P., & Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.51.1.203 · Cited by 122
Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms
Chase, T. N., Oh, J. D., & Konitsiotis, S. (2000) · Journal of Neurology · doi:10.1007/pl00007759 · Cited by 122
Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients
Gancher, S. T., Nutt, J. G., & Woodward, W. R. (1987) · Neurology · doi:10.1212/wnl.37.6.940 · Cited by 121
What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley, M. J., & Jenner, P. G. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.12.001 · Cited by 119
Self-citationMolecular basis of levodopa-induced dyskinesias.
Calon, F., Grondin, R., Morissette, M., Goulet, M., Blanchet, P. J., Paolo, T. D., & Bédard, P. J. (2000) · PubMed · Cited by 119
Oh, J. D., Vaughan, C. L., & Chase, T. N. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01121-x · Cited by 118
Regional, reversible ultrastructural changes in rat brain with chronic neuroleptic treatment
Meshul, C. K., & Casey, D. E. (1989) · Brain Research · doi:10.1016/0006-8993(89)90867-6 · Cited by 115
Vila, M., Lévy, R., Herrero, M. T., Faucheux, B. A., Obeso, J. A., Agid, Y., & Hirsch, É. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00549-8 · Cited by 114
Clarke, C. E., Sambrook, M. A., Mitchell, I., & Crossman, A. R. (1987) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(87)90041-4 · Cited by 114
Smith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2004) · Movement Disorders · doi:10.1002/mds.20317 · Cited by 113
Self-citationMorissette, M., Goulet, M., Soghomonian, J., Blanchet, P. J., Calon, F., Bédard, P. J., & Paolo, T. D. (1997) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00123-x · Cited by 112
Smith, L. A., Jackson, M. J., Al‐Barghouthy, G., Rose, S., Kuoppamäki, M., Olanow, C. W., & Jenner, P. G. (2005) · Movement Disorders · doi:10.1002/mds.20421 · Cited by 112
Self-citationThe MPTP-treated primate as a model of motor complications in PD
Jenner, P. G. (2003) · Neurology · doi:10.1212/wnl.61.6_suppl_3.s4 · Cited by 111
Self-citationLindgren, H. S., Ottosson, D. R., Ohlin, K. E., Lundblad, M., & Cenci, M. A. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.09.019 · Cited by 111
Calon, F., Morissette, M., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2002) · Movement Disorders · doi:10.1002/mds.10343 · Cited by 110
Is levodopa toxic to human substantia nigra?
Rajput, A. H., Fenton, M. E., Birdi, S., & Macaulay, R. J. B. (1997) · Movement Disorders · doi:10.1002/mds.870120503 · Cited by 109
Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Nutt, J. G. (2006) · Movement Disorders · doi:10.1002/mds.21060 · Cited by 109
Levodopa-induced dyskinesias in parkinsonian monkeys: Relationship to extent of nigrostriatal damage
Schneider, J. S. (1989) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(89)90372-9 · Cited by 108
New ideas on the origin of l-dopa-induced dyskinesias: age, genes and neural plasticity
Linazasoro, G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.06.007 · Cited by 108
Zeng, B. ‐., Pearce, R. K. B., MacKenzie, G. M., & Jenner, P. G. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00988.x · Cited by 107
Self-citationL -Dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations
Pearce, R. K. B., Heikkilä, M., I.-B., L. X. E. N., & Jenner, P. G. (2001) · Psychopharmacology · doi:10.1007/s002130100733 · Cited by 107
Self-citationTel, B. C., Zeng, B. ‐., Cannizzaro, C., Pearce, R. K. B., Rose, S., & Jenner, P. G. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00535-3 · Cited by 107
Self-citationBézard, E., Gross, C. E., Li, Q., Gurevich, V. V., Benovic, J., & Gurevich, E. V. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.10.005 · Cited by 105
Fox, S. H., Lang, A. E., & Brotchie, J. M. (2006) · Movement Disorders · doi:10.1002/mds.20936 · Cited by 105
Heimer, G., Rivlin‐Etzion, M., Bar‐Gad, I., Goldberg, J. A., Haber, S. N., & Bergman, H. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5140-05.2006 · Cited by 104
Striatal histone modifications in models of levodopa‐induced dyskinesia
Nicholas, A. P., Lubin, F. D., Hallett, P. J., Vattem, P., Ravenscroft, P., Bézard, E., Zhou, S., Fox, S. H., Brotchie, J. M., Sweatt, J. D., et al. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05417.x · Cited by 103
Nigrostriatal Damage is Required for Induction of Dyskinesias by l-DOPA in Squirrel Monkeys
Boyce, S., Rupniak, N. M. J., Steventon, M. J., et al. (1990) · Clinical Neuropharmacology · doi:10.1097/00002826-199010000-00006 · Cited by 101
Cao, X., Li, L., Hadcock, J. R., Iredale, P. A., Griffith, D. A., Menniti, F. S., Factor, S. A., Greenamyre, J. T., & Papa, S. M. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.125666 · Cited by 101
Sammut, S., Dec, A. M., Mitchell, D., Linardakis, J., Ortigüela, M., & West, A. R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300826 · Cited by 100
Industry forum: Progress in pursuit of therapeutic A2Aantagonists
Kase, H. (2003) · Neurology · doi:10.1212/01.wnl.0000095219.22086.31 · Cited by 99
Schuster, S., Nadjar, A., Guo, J. T., Li, Q., Ittrich, C., Hengerer, B., & Bézard, E. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4720-07.2008 · Cited by 95
Pathological Synaptic Plasticity in the Striatum: Implications for Parkinson's Disease
Picconi, B., Pisani, A., Barone, I., Bonsi, P., Centonze, D., Bernardi, G., & Calabresi, P. (2005) · NeuroToxicology · doi:10.1016/j.neuro.2005.02.002 · Cited by 94
Functional anatomy of movement disorders
Crossman, A. R. (2000) · Journal of Anatomy · doi:10.1046/j.1469-7580.2000.19640519.x · Cited by 94
Nash, J. E., Ravenscroft, P., McGuire, S., Crossman, A. R., Menniti, F. S., & Brotchie, J. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.004 · Cited by 94
Herrero, M. T., Lévy, R., Ruberg, M., Luquín, M. R., Villares, J., López-Guillén, J. L., Faucheux, B. A., Javoy-Agid, F., Guridi, J., Agid, Y., et al. (1996) · Neurology · doi:10.1212/wnl.47.1.219 · Cited by 92
Gubellini, P., Eusébio, A., Oueslati, A., Melon, C., Goff, L. K., & Salin, P. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05047.x · Cited by 91
Benabid, A. L., Chabardès, S., & Seigneuret, É. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000186839.53807.93 · Cited by 86
Aubert, I., Guigoni, C., Li, Q., Doveró, S., Bioulac, B. H., Gross, C. E., Crossman, A. R., Bloch, B., & Bézard, E. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.038 · Cited by 85
Guigoni, C., Doveró, S., Aubert, I., Li, Q., Bioulac, B. H., Bloch, B., Gurevich, E. V., Gross, C. E., & Bézard, E. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04196.x · Cited by 82
Striatal glutamatergic mechanisms and extrapyramidal movement disorders
Chase, T. N., Bibbiani, F., & Oh, J. D. (2003) · Neurotoxicity Research · doi:10.1007/bf03033378 · Cited by 78
Itoh, K., Oyanagi, K., Takahashi, H., SATO, T. A., Hashizume, Y., Shimmoto, M., & Sakuraba, H. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200001)47:1<122::aid-ana21>3.0.co;2-9 · Cited by 77
Modulation of striatal enkephalinergic neurons by antipsychotic drugs.
Hong, J., Yoshikawa, K., Kanamatsu, T., & Sabol, S. L. (1985) · PubMed · Cited by 77
Impact of pramipexole on the onset of levodopa‐related dyskinesias
Constantinescu, R., Romer, M. M., McDermott, M., Kamp, C., & Kieburtz, K. (2007) · Movement Disorders · doi:10.1002/mds.21292 · Cited by 74
Sustained Cabergoline Treatment Reverses Levodopa-Induced Dyskinesias in Parkinsonian Monkeys
Tahar, A. H., Grégoire, L., Bangassoro, E., & Bédard, P. J. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200007000-00005 · Cited by 73
Vila, M., Herrero, M. T., Lévy, R., et al. (1996) · Neurology · doi:10.1212/wnl.46.3.802 · Cited by 66
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2005) · Movement Disorders · doi:10.1002/mds.20654 · Cited by 65
Renaissance of amantadine in the treatment of Parkinson's disease.
Blanchet, P. J., Metman, L. V., & Chase, T. N. (2003) · PubMed · Cited by 64
Meshul, C. K., Janowsky, A. J., Casey, D. E., Stallbaumer, R. K., & Taylor, B. (1992) · Psychopharmacology · doi:10.1007/bf02253587 · Cited by 62
GDNF reverses priming for dyskinesia in MPTP‐treated, l ‐DOPA‐primed common marmosets
Iravani, M. M., Costa, S., Jackson, M. J., Tel, B. C., Cannizzaro, C., Pearce, R. K. B., & Jenner, P. G. (2001) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2001.01408.x · Cited by 59
Self-citationOh, J. D., & Chase, T. N. (2002) · Amino Acids · doi:10.1007/s00726-001-0118-2 · Cited by 58
Costa, S., Iravani, M. M., Pearce, R. K. B., & Jenner, P. G. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00933-x · Cited by 56
Self-citationDeutch, A. Y. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_12 · Cited by 55
Smith, L. A., Jackson, M. J., Johnston, L. C., Kuoppamäki, M., Rose, S., Al‐Barghouthy, G., Signore, S. D., & Jenner, P. G. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000220818.71231.df · Cited by 53
Self-citationEnhanced striatal opioid receptor-mediated G-protein activation in l-dopa-treated dyskinetic monkeys
Chen, L., Togasaki, D. M., Langston, J. W., Monte, D. A. D., & Quik, M. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.10.026 · Cited by 52
Striatal plasticity and extrapyramidal motor dysfunction
Chase, T. N. (2004) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2004.02.012 · Cited by 51
Calon, F., Morissette, M., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00064-9 · Cited by 50
Hurley, M. J., Jackson, M. J., Smith, L. A., Rose, S., & Jenner, P. G. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04169.x · Cited by 47
Self-citationJackson, M. J., Smith, L. A., Al‐Barghouthy, G., Rose, S., & Jenner, P. G. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.10.005 · Cited by 46
Self-citationAn update on the treatment of Parkinson's disease.
Jankovic, J. J. (2006) · PubMed · Cited by 45
Hurley, M. J., Jolkkonen, J., Stubbs, C. M., et al. (1996) · Brain Research · doi:10.1016/0006-8993(95)01309-1 · Cited by 44
Deep brain stimulation for the treatment of Parkinson’s disease
Hamani, C., Neimat, J. S., & Lozano, A. M. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_59 · Cited by 43
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2006) · Synapse · doi:10.1002/syn.20295 · Cited by 43
Schneider, J. S., Gonczi, H., & Decamp, E. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03382-1 · Cited by 43
Levodopa response motor complications—GABA receptors and preproenkephalin expression in human brain
Calon, F., & Paolo, T. D. (2002) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(02)00029-9 · Cited by 43
Proteomic analysis of striatal proteins in a rat model of L-DOPA-induced dyskinesia
Valastro, B., Dekundy, A., Krogh, M., Lundblad, M., James, P., Danysz, W., Quack, G., & Cenci, M. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04655.x · Cited by 40
Kultima, K., Scholz, B., Alm, H., Sköld, K., Svensson, M., Crossman, A. R., Bézard, E., Andrén, P. E., & Lönnstedt, I. M. (2006) · BMC Bioinformatics · doi:10.1186/1471-2105-7-475 · Cited by 39
Calon, F., Morissette, M., Goulet, M., Grondin, R., Blanchet, P. J., Bédard, P. J., & Paolo, T. D. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7366 · Cited by 37
Clinical trials with rasagiline: Evidence for short-term and long-term effects
Siderowf, A. D., & Stern, M. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s80 · Cited by 29
Bassilana, F., Mace, N., Li, Q., Stutzmann, J. M., Gross, C. E., Pradier, L., Bénavidès, J., Ménager, J., & Bézard, E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.02.005 · Cited by 29
PET studies and motor complications in Parkinson's disease
Brooks, D. J. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00016-1 · Cited by 28
Oh, J. D., Chartisathian, K., Ahmed, S. M., & Chase, T. N. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10629 · Cited by 25
Use of apomorphine in Parkinson's disease
O’Sullivan, J. D., & Lees, A. J. (1999) · Hospital Medicine · doi:10.12968/hosp.1999.60.11.1236 · Cited by 23
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia
Hallett, P. J., & Brotchie, J. M. (2006) · Movement Disorders · doi:10.1002/mds.21163 · Cited by 23
Nutt, J. G. (1995) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1995.tb01946.x · Cited by 21
Pathophysiologic basis of tardive dyskinesia.
Rj, B., & Tarsy, D. (1980) · PubMed · Cited by 20
Surgical therapy for Parkinson’s disease
Benabid, A., Chabardès, S., Seigneuret, É., Fraix, V., Krack, P., Pollak, P., Xia, R., Wallace, B. A., & Sauter, F. (2006) · Springer eBooks · doi:10.1007/978-3-211-45295-0_58 · Cited by 19
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa
Togasaki, D. M., Protell, P., TAN, L., WILLIAMLANGSTON, J., Monte, D. A. D., & Quik, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.10.009 · Cited by 16
Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys
Cohen, R. M., Carson, R. E., Aigner, T. G., & Doudet, D. J. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00777-x · Cited by 15
Samadi, P., Morissette, M., Calon, F., Tahar, A. H., Dridi, M., Bélanger, N., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2007) · Synapse · doi:10.1002/syn.20469 · Cited by 11
Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP
Cohen, R. M., Carson, R. E., Wyatt, R. J., & Doudet, D. J. (1999) · Synapse · Cited by 10
Lee, J., Gómez-Ramírez, J., Johnston, T. H., Visanji, N. P., & Brotchie, J. M. (2008) · Synapse · doi:10.1002/syn.20481 · Cited by 9
Cited by
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Direct and indirect pathways of basal ganglia: a critical reappraisal
Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., & Di Filippo, M. (2014) · Nature Neuroscience · doi:10.1038/nn.3743 · Cited by 828
Basal Ganglia Disorders Associated with Imbalances in the Striatal Striosome and Matrix Compartments
Crittenden, J. R., & Graybiel, A. M. (2011) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2011.00059 · Cited by 481
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P.-O., Feyder, M., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 475
Olivares, D., K. Deshpande, V., Shi, Y., K. Lahiri, D., H. Greig, N., T. Rogers, J., & Huang, X. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322564 · Cited by 407
Metadata
- Authors
- Jenner, P.
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-09
- Volume
- 9
- Issue
- 9
- Pages
- 665-677
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W1980202815
- Cited by
- 523
- References
- 183
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.